To the full analysis
Hansa Biopharma stock: growth
HNSA.STHansa Biopharma reported $22.29M in revenue for fiscal 2025, up 29.7% on the prior year, up 105.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
57%
per year from 2008 to 2025, per share 33.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2008 | |
|---|---|---|---|
| Revenue | 105.3% | 44.9% | 57.0% |
| Revenue per share | 80.1% | 31.7% | 33.3% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2008 | $10.4K | −$256.51K | −$1.96M |
| 2009 | $299.19K | −$1.59M | −$1.38M |
| 2010 | $446.03K | −$1.89M | −$1.81M |
| 2011 | $128.57K | −$2.46M | −$2.72M |
| 2012 | $262.59K | −$1.65M | −$2.34M |
| 2013 | $173.17K | −$1.76M | −$1.5M |
| 2014 | $472.88K | −$2.91M | −$2.49M |
| 2015 | $544.88K | −$6.64M | −$5.93M |
| 2016 | $258.6K | −$11.14M | −$9.58M |
| 2017 | $345.13K | −$17.71M | −$15.29M |
| 2018 | $336.71K | −$24.86M | −$20.76M |
| 2019 | $337.31K | −$36.1M | −$33.91M |
| 2020 | $611.46K | −$42.2M | −$29.14M |
| 2021 | $3.4M | −$54.98M | −$48.49M |
| 2022 | $15.49M | −$61.28M | −$50.74M |
| 2023 | $13.45M | −$83.4M | −$75.8M |
| 2024 | $17.18M | −$80.94M | −$67.68M |
| 2025 | $22.29M | −$53.56M | −$55.07M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.